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Introduction
Narcolepsy with cataplexy (also called Narcolepsy type 1) is a disabling disorder primarily due to the specific loss of hypocretin (Hcrt, also called orexin) neurons (Scammell, 2015) . The underlying disease mechanism remains unknown. However, current available data support an autoimmune destruction of the Hcrt-producing neurons as the most likely hypothesis (Degn and Kornum, 2015; Liblau et al., 2015) . There are essentially two lines of evidence for such a mechanism: genetic findings-especially the extremely tight association with the HLA-DQB1*06:02 allele; and epidemiological findings-the observation of increased incidence of childhood narcolepsy after Pandemrix Õ H1N1 vaccination (Liblau et al., 2015) . A genome-wide association study (GWAS) found an association between narcolepsy with cataplexy and a single nucleotide polymorphism (SNP) (rs2305795) in the 3'UTR of the purinergic receptor subtype P2RY11 gene on chromosome 19p13.2 (Kornum et al., 2011) . This association was replicated in several populations (Han et al., 2012 (Han et al., , 2013 Tafti et al., 2014; Yamasaki et al., 2016) . P2Y 11 receptors are activated by extracellular ATP and differ from other purinergic receptor as they couple to both Gq and Gs, releasing calcium (Ca 2 + ) through the phosphatidylinositol pathway and producing cAMP by activation of the adenylate cyclase (Communi et al., 1999) . Little is known about the function of P2Y 11, mainly because of its absence in rodents. In humans, P2RY11 is expressed by the immune cells, especially CD8 + T cells and NK cells (Torres et al., 2002; Kornum et al., 2011) . The associated P2RY11 narcolepsy genotype correlates with reduced expression of P2RY11 in CD8 + T cells and NK cells, and the low-expression variant has been reported to be associated with reduced resistance to ATP-induced cell death (Kornum et al., 2011) . Altogether these findings suggest that a decreased P2Y 11 function might increase the risk of developing narcolepsy with cataplexy.
We performed exome sequencing in 18 familial narcolepsy with cataplexy cases and found two different nonsynonymous mutations in the second exon of P2RY11. We also sequenced the coding region of P2RY11 in 250 patients with non-familial narcolepsy with cataplexy and found six additional non-synonymous mutations, without finding any mutation in 135 healthy controls. We further investigated functional consequences of the identified P2RY11 mutations in vitro. Finally we quantified P2Y 11 protein and mRNA expression in lymphocytes from four narcolepsy with cataplexy patients carrying P2RY11 mutations and their first-degree relatives.
Materials and methods

Subjects
All patients (n = 268) diagnosed with narcolepsy with cataplexy and controls (n = 135) were recruited in a single sleep disorder center, the National Reference Center for Narcolepsy, Montpellier, France.
We included 18 patients [nine males and nine females, mean age 42.8 AE 10.2 years (range 25-65)] with familial narcolepsy with clear-cut cataplexy defined by at least two family members affected with narcolepsy with cataplexy. All patients had excessive daytime sleepiness, cataplexy, and with positive multiple sleep latency test (MSLT) findings except a few of them with either MSLT latency 510 min instead of 8 min or one sleep onset REM period instead of two. The mean age at onset was 17.1 AE 7.5 years (range 8-38), mean body mass index (BMI) of 27.6 AE 4.5 (16% with BMI 4 30), and mean Epworth sleepiness scale at baseline at 20.1 AE 3.0. All but one (HLA-DQB1*06:04/02:01) were positive for HLA-DQB1*06:02. We performed a lumbar puncture in 4 of 18 patients and all had low CSF Hcrt-1 levels (5110 pg/ml). Fifteen probands had one other affected family member with narcolepsy with cataplexy, two had three affected members, and one had four affected members.
Two hundred and fifty patients [148 males and 102 females, mean age at 39.3 AE 20.2 years (range 4-86)] with non-familial narcolepsy with excessive daytime sleepiness, clear-cut cataplexy, and HLA-DQB1*06:02 positive were included. The mean age at onset was 22.1 AE 11.0 years (range 3-51), mean BMI at 25.57 AE 4.73 (15% with BMI 4 30), and mean Epworth sleepiness scale at baseline at 17.4 AE 3.8. All patients had positive MSLT findings but 22 (8.8%) had either MSLT latency 510 min instead of 8 min or one sleep onset REM period instead of two, as has been reported, especially depending on the age in sporadic narcoleptic patients (Dauvilliers et al., 2004) . We performed a lumbar puncture in 63 patients and all but one (459 pg/ml with typical video-recorded cataplexy, mean MSLT 5 8 min and one sleep onset REM period) had low CSF Hcrt-1 levels (5110 pg/ml).
One hundred and thirty-five control subjects [65 males and 70 females, mean age at 30.3 AE 12.3 years (range 6-66)], mean BMI at 22.8 AE 4.4 (with 3.7% with BMI 4 30), and mean Epworth sleepiness scale at baseline at 5.9 AE 4.3 were included. Among them, 26 (19.2%) subjects were HLA-DQB1*06:02 positive. We included in both populations (narcoleptic patients and control subjects) a few African and North African subjects. Overall, all except 16 sporadic cases (94%) and all except five controls (96%) were Caucasian with European origin.
This study was approved by the institutional review board of the University of Montpellier-France. The methods were carried out in accordance with the approved guidelines. Each participant signed an informed consent form.
Exome sequencing DNA was extracted from peripheral blood using standard technique from the 18 familial narcolepsy with cataplexy probands and 14 of their relatives (seven affected and seven unaffected) from eight families (in 10 families only the proband was available). Among seven affected relatives all but one were HLA-DQB1*06:02 positive. Among seven unaffected relatives all but two were HLA-DQB1*06:02 positive.
Exomes were captured using Agilent SureSelect Human All Exon v3 and v4 enrichment kits and sequenced on Illumina HiSeq 2500 platform. Purity-filtered reads were adapted and quality trimmed with FastqMcf (v. 1.1.2), and aligned to the human genome (hg19) using BWA (v. 0.6.2, Li, 2009) . PCR duplicates were marked using Picard tools (v. 1.80, http:// picard.sourceforge.net). BAM files were further processed with GATK (v. 2.8.1) for realignment around indels and base quality score recalibration (Van der Auwera et al., 2013) . Variant calling and quality filtering were performed on all samples using GATK UnifiedGenotyper and GATK Variant Quality Score Recalibration (DePristo et al., 2011) . Multi-allelic variants in the VCF file were decomposed into one entry per allele. Variants were annotated with SnpEff (Cingolani et al., 2012) and Annovar (Wang et al., 2010) . The filtering strategy to identify candidate variants was designed to account for incomplete penetrance and a dominant mode of inheritance. The criteria to retain a variant were: (i) splice site or exonic location (but not synonymous); (ii) population frequency 50.1% in 1000 Genomes (Auton et al., 2015) and exome sequencing project (Fu et al., 2013) ; (iii) CADD (http://cadd.gs.washington.edu/) score 510 (Kircher et al., 2014) ; (iv) VQSR filter = 'PASS'; (v) not found in more than two unaffected samples among all sequenced samples; (vi) not found in more than 10% of all the sequenced sample; (vii) not found in more than one unaffected sample inside a particular family; and (viii) not homozygote. Genes with variants passing the filtering criteria in at least two families were further evaluated for known associations with disease using the BioGPS portal (Wu et al., 2009) .
SNP genotyping and P2RY11 resequencing
Genotyping of rs2305795 was performed by Sanger sequencing (forward 5'-CAGACACCCAAGTGGCATCT-3', reverse 5'-CGACCACCTCATCCTCAACG-3'). The P2RY11 second exon was sequenced by Sanger sequencing with two overlapping primer pairs (forward 1: 5'-GGGGAAAGAACTCGT GTCCA-3', reverse 1: 5'-GCTATACGCTCTGTAGGCCG-3'; forward 2: 5'-GAGGCCTGCATCAAGTGTCT-3', reverse 2: 5-'CCAGCAACACCTAGGGTGAG-3').
Site-directed mutagenesis
The EX-Z1416-M56 vector (GeneCopoeia TM ) with a C-terminal mCherry tagged human P2RY11 was used as template for site directed mutagenesis. Mutations were introduced using the QuikChange Lightning Site-Directed mutagenesis kit (#210518, Agilent Technologies) (see Supplementary Table 2 for primer sequences). All mutations were verified by sequencing (Eurofins Genomics Sequencing).
Cell culture and transfection
Grip Tite TM HEK293 cells (kind gift from Søren G Faarup Rasmussen, University of Copenhagen) were maintained in complete medium; Dulbecco's modified Eagle medium (DMEM, #L0102-500, Biowest) with 10% foetal bovine serum (FBS) and 1% non-essential amino acids (NEAA, #11140-035, Gibco, Life Technologies), penicillin-streptomycin (P/S, #DE17-602B, Lonza), and Geneticin Õ Selective Antibiotic G418 Sulfate (#10131-019, Gibco) at 37 C in 5% CO 2 . Cells (1.2 Â 10 6 ) were plated in a 6-well plates with fresh medium (DMEM with 2% FBS and 1 Â NEAA). The cells were transfected with Lipofectamine TM 2000 Transfection Reagent (#11668-019, Invitrogen, Life Technologies) according to the manufacturer's recommendation in 5 ml ampicillin free complete medium with 250 ml transfection reagent with 2.4 mg DNA (0.34 mg/ml). Cells were transfected overnight. Transfection medium was removed the following day and cells were washed in phosphate-buffered saline (PBS) and loosened with Versene Õ and trypsin before seeding for calcium and cAMP assays.
Calcium measurement
Live cells (3 Â 10 5 per well) were plated in a 96-well plate and left to adhere overnight at 37 C in 5% CO 2 . The medium was replaced with 200 ml wash buffer (20 mM HEPES, 1 mM MgCl 2 , 2 mM CaCl 2 in Hank's balanced salt solution pH 7.4) per well. Fifty microlitres of Fluo-4 loading buffer [4 mM Fluo-4 (#F14201, Molecular Probes) in DMSO, and 2 ml/ml pluronic acid in washing buffer], blank wells received 50 ml washing buffer. Cells were incubated for 30 min at 37 C in 5% CO 2 before calcium imaging. The stable ATP analogue, 3'-O-(4-benzoyl)benzoyl-ATP (BzATP, #B6396-25MG, Sigma) was automatically added of the wells and the signal was detected using the NOVOstar microplate reader system (BMG Labtech). Raw data were plotted as time-response curves and the maximal fluorescence intensity above baseline was calculated relative to baseline. These values were used to calculate the average background from the three lowest tested concentrations showing no response. The normalized response was calculated by subtracting the average background value from each sample in the dose-response curve. The maximum response was used for normalization and the EC50 values were calculated from the dose-response curve.
cAMP measurement
Grip Tite TM HEK293 cells were grown and stimulated with 2 0 (3 0 )-O-(4-benzoylbenzoyl)adenosine-5 0 -triphosphate tri(trieth ylammonium) salt (BzATP) (Sigma-Aldrich) in a 96 wells plate. cAMP was quantified by direct ELISA kit (#ADI-900-066, Enzo). Briefly, the medium was removed and cells lysed by adding 50 ml 0.1 M HCl to the wells for 10 min at room temperature. Cellular debris was removed by 5 min centrifugation at 600g, and the supernatant was used for cAMP measurement. Standards and samples were acetylated by adding 10 ml 1:2 acetic anhydride:triethylamine per 200 ml sample. One hundred microlitre samples and standards were added to each well along with alkaline phosphatase conjugated cAMP and anti-cAMP rabbit polyclonal antibody. The plates were incubated for 2 h with shaking at room temperature. After incubation, the plates were washed three times with washing buffer. Substrate solution (200 ml) was added and the reaction allowed to run for 1 h at room temperature before stopping the reaction with Stop Solution. The ELISA plates were read at 405 nm optical density on a Tecan M200. Sample concentrations were calculated using a 4-parameter logistic curve fitting of the included standard curve.
Flow cytometry
Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed and allowed to rest in cell culture medium (RPMI with 10% FBS) for 2 h before staining for flow cytometry. Cells were washed with PBS and stained for viability with Fixable Viability Stain e506 (eBiosciences) followed by two washes with PBS with 0.5% human serum. Blocking for non-specific binding was performed in PBS with 10% human serum and FC-blocker (BD Biosciences) for 15 min at room temperature. Staining for surface markers CD3-BV421, CD4-FITC, CD8-PE-Cy7 and CD56-PE (all BD Biosciences) was performed for 30 min at 4 C. From this point onwards, the cells were either stained for P2Y 11 antibody (#183096, Abcam), with specificity towards P2Y 11 previously confirmed in transfected HEK cells (Dreisig et al., 2016) or stained for P2RY11 mRNA using the PRIMEflow (Affymetrix) assay. Intracellular staining with Lightning Link Õ (Innova Biosciences) APC conjugated P2Y 11 antibody was performed in Fix/Permabilization kit (eBiosciences) for 45 min on ice according to the manufacturer's recommendations. All samples were assayed as technical duplicates and the average value is reported. RNA flow cytometry was run in 96-well plates according to the protocol provided with the PRIMEflow kit using the human P2RY11 probe (#VA1-10649, eBiosciences). The exact sequence of the probe is not available, but it covers bases 2-1543 and is not affected by single point mutations. Samples were measured on a FACSverse flow cytometer (BD Biosciences) and analysed with the FACSuite software.
Results
Identification of eight different P2RY11 missense mutations in narcolepsy with cataplexy
Exome sequencing of the 18 familial narcolepsy patients with cataplexy revealed two patients with different nonsynonymous mutations in the second exon of P2RY11 (NM_002566:exon 2) (Tables 1 and 2) . A c.T961C (p.Y321H) mutation located in the seventh transmembrane domain (TM7) of P2Y 11 was found in Patient 9 (HLA-DQB1*06:02/02:01-positive) and in his other affected family member (e.g. son, narcoleptic with cataplexy, HLA-DQB1*06:02 negative) but not in his unaffected daughter (Table 1) . A c.G556A (p.E186K) mutation located in the second extracellular loop (ECL2) of P2Y 11 was found in Patient 5 (North-African origin, HLA-DQB1*06:04/02:01-positive) with the mother also having narcolepsy with cataplexy but not available for sequencing ( Table 1) .
The coding sequence of P2RY11 was next sequenced (Sanger) in 250 sporadic narcolepsy with cataplexy cases and 135 healthy controls. Six additional non-synonymous P2RY11 mutations were found in patients with narcolepsy, whereas none were found in the control group (one-tailed Fisher exact test P 5 0.05). Seven of the eight P2RY11 mutations identified in narcolepsy were present in the dbSNP database with very low frequencies ( Table 2 ). The c.C961T mutation leading to an exchange of tyrosine to histidine at position 321 in TM7 has not previously been reported. One mutation c.C286T (p.R96C) was found in two probands from two unrelated families. One of them (Patient 2) is a typical narcolepsy with cataplexy patient but possibly triggered by H1N1 vaccination with a delay of 3 months between vaccination and onset of symptoms (Tables 1 and  2 ). The mutation c.A782G (p.Y261C) was found in a patient with narcolepsy with cataplexy, HLA-DQB1*06:02 homozygous but with normal CSF Hcrt-1 levels, and a comorbid inflammatory CNS disorder of unclear origin. The four other P2RY11 mutations were found in typical patients with narcolepsy with cataplexy. In three cases, DNA from both unaffected parents was available and sequenced (Table 3) . In all three, the mutation was found in one of the parents (in two cases the father, and in one the mother) indicating that these mutations are not de novo. In another patient (Patient 8), DNA of the unaffected son was available, and no mutation was found. All sporadic cases with P2RY11 mutations were HLA-DQB1*06:02 positive. Interestingly eight of nine patients with a P2RY11 mutation also carried the P2RY11 narcolepsy associated rs2305795 A allele [minor allele frequency (MAF) = 0.3444] and five were homozygous (Table 1) . Additionally in Patients 1-3, the mutation was transmitted together with the A allele from one of the two heterozygous parents (Table 3) .
Functional analyses of P2RY11 mutations
Narcolepsy-associated P2RY11 mutations were found throughout the protein (Fig. 1) . To investigate the functional consequences of the P2RY11 mutations, we stimulated P2RY11 transfected GripTite TM HEK293 cells with the agonist BzATP and determined the intracellular concentrations of cAMP and Ca 2 + . The affinity of the BzATP ligand towards P2Y 11 is comparable with the endogenous agonist ATP and is much higher than towards P2Y 1 or P2X7 (White et al., 2003) . Mock-transfected cells did not respond to BzATP stimulation showing that the cells did not express P2Y 11 endogenously. Variable responses were found among mutations (Fig. 2, Supplementary Figs 1 and  2) . The p.R307W mutation completely abolished both Ca 2 + and cAMP signalling, suggesting a complete loss-offunction. The p.R96C mutation that occurred in two patients, severely decreased potency of BzATP at P2Y 11 by 30-fold for Ca 2 + and 300-fold for cAMP. p.E186K and p.Y261C also significantly decreased signalling to both cAMP and Ca 2 + . In contrast, two mutations (p.A64T and p.S166G) were indistinguishable from the wild-type P2RY11. The remaining mutations gave mixed results: p.Y321H showed decreased release of Ca 2 + by 10-fold without affecting the cAMP signal, while p.V272M, showed an almost 10-fold increased cAMP response after BzATP stimulation without any change in Ca 2 + signalling.
Functional consequences of P2RY11 mutations depend on their location in the receptor P2Y 11 is a G-protein coupled receptor of the P2Y receptor family. The structure of P2Y 11 is not known, but it is likely to be highly similar to P2Y 1 (Communi et al., 1999) , allowing P2Y 1 to serve as a model for P2Y 11 (von Kugelgen and Hoffmann, 2016) . The P2RY11 mutations found in narcolepsy with cataplexy patients were dispersed throughout the receptor and located in ECL1 and ECL2 as well as in TM2, TM6 and TM7 ( Fig. 1 and Table 2 ). All the mutated P2Y11 positions are highly conserved from Sus scrofa (wild boar) and three of the positions are conserved in Danio renio (zebrafish), indicating potential functional relevance ( Supplementary Fig. 5 ). In contrast, only the p.Y321 position is conserved among the most closely related members of the human P2Y receptors (Supplementary Fig. 6 ). The mutation in ECL1 at position 96 was carried by two patients. This mutation resulted in severely decreased potency of BzATP, thus affecting both Ca 2 + and cAMP signalling. This result indicates that this position, which is not conserved in P2Y 1 or other P2Y receptors, might influence the ligand binding.
ECL2 and ECL3 are considerably longer in P2Y 11 compared to P2Y 1 and other members of the P2Y-receptor family, and the role of these loops for ligand recognition and binding has not yet been clarified (Zylberg et al., 2007) . The p.E186K mutation in ECL2 was found in a family with hereditary narcolepsy, and this mutation resulted in a significantly decreased signalling by both cAMP and Ca 2 + . In a P2Y 11 -P2Y 1 pairwise alignment, P2Y 11 position 186 aligns with the negative p.D204 in P2Y 1 and mutations at this position to a neutral amino acid reduced inositol phosphate accumulation in cells in response to the agonist (Hoffmann et al., 1999) . Therefore, position 186 appears to be important for signalling through both Gs and Gq and has also been shown to be important for diastereo-selectivity to P2Y 11 ligands ( Ecke et al., 2008) . The other mutation in ECL2 p.S166G was indistinguishable from the wild-type P2Y 11 , as was the mutation in TM2 c.G190A. The integrity of TM3, TM6 and TM7 is known to be essential for P2Y 11 activation (Moro et al., 1998; Qi et al., 2001; Costanzi et al., 2004; Zylberg et al., 2007) . In the narcolepsy cohort, we identified two mutations in TM6 and two in TM7. The TM6 mutation p.Y261C was found in a patient with narcolepsy with cataplexy and comorbid CNS inflammatory disorder and normal Hcrt-1 levels. This mutation resulted in significantly decreased signalling by both cAMP and Ca 2 + . This result is in agreement with previous work showing that a mutation from tyrosine to alanine at this position abolishes Ca 2 + signalling (Zylberg et al., 2007) . Position 261 is unlikely to interact directly with the ATP-docking site, but acts as a molecular switch stabilizing the structure of the receptor (Zylberg et al., 2007) . Moreover, work on P2Y 1 demonstrated that a mutation of the homologous position (p.Y273) to alanine led to a functionally inactive receptor, although ligand binding remained unaltered (Costanzi et al., 2004; Ecke et al., 2006) . The mutation at position 272 has not previously been investigated for P2Y 11 and the position is not conserved among P2Y receptors (Jacobson et al., 2015) (Supplementary Fig.  6 ), but is likely located close to the extracellular end of TM6. The p.V272M mutation resulted in increased coupling to adenylate cyclase but normal Ca 2 + response. The mechanism responsible for the increased cAMP response is unknown, but we speculate that this mutation may stabilize a conformation of the receptor with increased affinity for ligands such as Gs.
The p.R307W mutation located central to the TM7 completely abolished both Ca 2 + and cAMP signalling, in agreement with previous studies on the P2Y 1 showing that a positive charge at this conserved location is crucial for ATP binding (Moro et al., 1998; Costanzi et al., 2004) . Mutation at P2RY1 p.A310, which is homologous to P2RY11 p.R307, almost completely abolishes Ca 2 + signalling (Jiang et al., 1997; Zylberg et al., 2007) . The effect of the second mutation in TM7 (the conserved tyrosine in position 321) has not previously been investigated for any of the receptors in the P2Y family. This position does not seem to affect ligand binding, but may be involved in the coupling to Gq. Accordingly, we found that this mutation led to a right shift of the dose-response curve for Ca 2 + by 10-fold without affecting cAMP.
Altogether, we found significant functional consequences of most of the identified mutations, with the exact nature of the defects depending on the localization of the mutation.
Expression pattern of P2RY11 in T cells from patients and relatives carrying mutations
We next analysed PBMCs by flow cytometry to quantify protein and mRNA expression of P2RY11 in both CD4 + and CD8 + T cells and NK cells from four patients with sporadic narcolepsy with cataplexy carrying P2RY11 mutations and their first-degree unaffected relatives: both parents for three of them (i.e. two from patients with the R96C mutation and one with the A64T mutation) and one son for the fourth case (the R307W loss-of-function mutation) ( Table 3) .
As expected, the P2Y 11 receptor was expressed in both CD4 + and CD8 + T cells as well as NK cells. All cells in the studied populations expressed the P2Y 11 receptor but with varying intensity. Median fluorescence intensity was slightly decreased in the patients compared to their unaffected relatives (Fig. 3) , but large interindividual differences were seen independent of the P2RY11 mutations. Curiously, overall at protein level P2Y 11 showed equal amounts in CD4 + and CD8 + T cells in contrast to what has been reported for mRNA expression levels (Kornum et al., 2011) .
To address if the observed changes in P2Y 11 expression reflected differences in transcription, we investigated the P2RY11 mRNA at a single cell level. The P2RY11 mRNA was expressed in all investigated cells and the levels were comparable in 10 among the 11 investigated samples. Thus individual mRNA expression levels did not correlate with disease status or different mutations ( Supplementary Fig. 4 ).
Discussion
Our exome sequencing in 18 familial and 250 sporadic patients with narcolepsy with cataplexy compared to 135 healthy controls revealed eight non-synonymous mutations in the second exon of P2RY11, one of which has not previously been described. These missense mutations were found in nine patients including two familial cases. Two of the sporadic cases carried the same mutation. We demonstrated major functional consequences of six of the identified mutations by assessing the Ca 2 + release and the activation of adenylate cyclase in cells transfected with vectors carrying the individual mutations. We found a lower P2Y 11 protein but not mRNA expression in three patients carrying P2RY11 mutations, suggesting that some of the mutations alter the receptor stability.
Common SNPs in P2RY11 and in the overlapping gene EIF3G have previously been reported to be associated with narcolepsy (Kornum et al., 2011; Tafti et al., 2014; Holm et al., 2015) . The effect size is, however, small, and because of high linkage disequilibrium across the loci it has not been possible to identify a single causal variant (Holm et al., 2015) . All but one of the patients carrying rare P2RY11 mutations also carried the narcolepsy-associated allele of the common variant rs2305795. The finding of both rare and common disease-associated variants within the same loci is often seen as for example in ulcerative colitis (Beaudoin et al., 2013) and restless legs syndrome (Schulte et al., 2014) . Our findings thus emphasize the receptor. Patient (green), parent carrying the mutation (red) and non-carrying parent (black) line. Histograms for CD4 + T cells and NK cells can be found in Supplementary Fig. 3 .
functional importance of the P2RY11 loci in narcolepsy with cataplexy. Given the number of patients investigated, the low frequency of mutations reported in the general population and the absence of mutations in our healthy control group, the number of missense mutations discovered were surprisingly high, which supports a relationship between reduced P2Y 11 function and the development of narcolepsy with cataplexy. P2RY11 mutations were found in typical sporadic narcolepsy with cataplexy patients, familial narcolepsy with cataplexy patients but also in some atypical cases with normal CSF Hcrt-1 level or HLA-DQB1*06:02 negative. Based on our results we cannot conclude whether P2RY11 mutations are more frequent in atypical narcolepsy with cataplexy cases in terms of HLA negativity (n = 1 proband among 9) and/or normal CSF Hcrt-1 (n = 1 among 5 with CSF measurement). Further studies are required to answer this clinically relevant question.
In the two families where a mutation was found, one was documented as inherited. In the other familial case, DNA from the parents was not available for analysis. For sporadic cases, in four patients the mutation was found in one of the parents (unaffected), despite two of these parents also being HLA-DQB1*06:02 positive, indicating that none of the reported mutations are de novo but with incomplete penetrance. Incomplete penetrance is often seen with rare mutations (Cooper et al., 2013) . Note that in two cases (Patients 2 and 3, Table 3), the unaffected carriers of the mutation were HLA-DQB1*05:01 positive, known to be a protective allele in narcolepsy with cataplexy (Tafti et al., 2014) . In our documented familial case with a highly penetrant P2RY11 mutation (Patient 9), the mutation (p.Y321H) decreased the release of Ca 2 + by 10-fold without affecting the cAMP signal pointing to the Ca 2 + signalling pathway as the most important with regard to narcolepsy pathogenesis.
The endogenous ligand of P2Y 11 is extracellular ATP and the activated receptor recruit Gq and Gs, leading to Ca 2 + release and activation of the adenylate cyclase (Communi et al., 1999) . While the ATP receptor function is likely to be involved, the mechanistic relevance of P2Y 11 in narcolepsy remains unknown, in part because of the lack of any clear P2Y 11 homolog in mouse and rat. Interestingly, the different mutations that we observe in our study have quite diverse effects on the BzATP induced cAMP and Ca 2 + response. This suggests that any kind of imbalance in P2Y 11 response can lead to narcolepsy development. Another P2RY11 missense mutation has been found to be associated with acute myocardial infarction (AMI) (Amisten et al., 2007; Haas et al., 2014) . This mutation [p.A87T (rs3745601)] is a more common SNP (MAF = 0.159, dbSNP), and is also associated with increased inflammatory marker C-reactive protein (Amisten et al., 2007; Haas et al., 2014) . We did not find this SNP in any of the narcolepsy cases, in accordance with a previous study reporting no association in narcolepsy with rs3745601 (Kornum et al., 2011) . Interestingly p.A87T does not alter either Ca 2 + or cAMP signalling to any significant extend (Fig. 2  and Table 3 ), but has instead been reported to alter P2Y 11 internalization. This suggests that P2Y 11 plays different roles in the pathogenesis of narcolepsy versus AMI, with decreased signalling being especially important in the development of narcolepsy.
We confirmed the expression of P2RY11 in CD4 + and CD8 + T cells and NK cells by single cell mRNA expression analysis and furthermore showed that these types of cells express the P2Y 11 protein. Due to the lack of good antibodies towards extracellular receptor epitopes, we were unable to determine the degree of surface expression in these cells (data not shown). We found a globally reduced P2Y 11 protein expression in patients especially in CD8 + T cells and NK cells compared to healthy relatives, but this was not directly related to P2RY11 mutations since the same effect was not seen in healthy carriers. Moreover, mRNA expression levels did not significantly differ between patients and unaffected relatives. PBMCs were obtained from only four probands carrying the mutations and seven unaffected relatives including three carrying the mutations, but more studies are needed to determine the influence of the P2RY11 mutations on receptor stability and expression in vivo.
The reduced P2Y 11 protein expression in CD8 + T cells in patients with different mutations might have implications for narcolepsy and other autoimmune diseases. P2RY11 expression is widespread in immune cells but particularly high in CD8 + cells (Kornum et al., 2011) , as supported by our flow cytometry findings. Previous studies found that increased ATP concentration induces PBMC death while stimulation of purinergic receptors including P2Y 11 modulates this effect (Kornum et al., 2011) . Stimulation of P2Y 11 further delays spontaneous apoptosis in neutrophils (Vaughan et al., 2007) . Recent data showed that the activation of P2Y 11 in monocytic-derived dendritic cells released IL8 and decreased IL12, further supporting the immunomodulatory role of P2Y 11 (Wilkin et al., 2001; Marteau et al., 2004; Meis et al., 2010) . Interestingly, studies of cytokine levels in serum from narcolepsy with cataplexy patients compared to controls have suggested lower IL8 and higher IL12 levels close to disease onset Lecendreux et al., 2015) . We speculate that P2RY11 mutations may regulate CD8 + T cell function and affect their interaction with Hcrt neurons. A post-mortem histopathology study of a single brain from a patient with Hcrt deficient narcolepsy with cataplexy and Ma2 paraneoplastic syndrome revealed marked inflammation dominated by cytotoxic CD8 + T cells and tissue injury in the hypothalamus with complete loss of Hcrt neurons (Dauvilliers et al., 2013) . P2RY11 mRNA is also detected in the human brain including the hypothalamus (Moore et al., 2001) where the Hcrt neurons are located, but the precise cellular location is unknown.
In conclusion, we found eight different P2RY11 non-synonymous mutations in nine patients with familial or sporadic narcolepsy with cataplexy from a single narcolepsy sleep centre, a finding much higher than expected based on allele frequencies in databases and when compared with a healthy control population. Most of these mutations had key functional consequences at cellular level on the release of intracellular cAMP and Ca 2 + . They may further alter P2Y 11 protein stability, especially in the cytotoxic immune cells. Our findings suggest that functional changes caused by mutations in P2RY11 might dysregulate the function of cytotoxic CD8 + T-cells and their potential interaction with Hcrt neurons. This could in combination with other risk factors (HLA genes) lead to the development of narcolepsy with Hcrt deficiency. It is currently unknown if P2Y 11 is expressed by Hcrt neurons, thus it is also possible that P2RY11 mutations directly affect Hcrt neurons.
